New Lung Cancer Medication

Tuesday, 16 Jul 2013 09:35 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
The drug Gilotrif (afatinib) has been approved by the U.S. Food and Drug Administration to treat spreading cases of non-small cell lung cancer (NSCLC) caused by certain gene mutations.
The treatment, given priority FDA review, was sanctioned for tumors that express certain epidermal growth factor receptor (EGFR) mutations, as detected by a newly approved diagnostic, the agency said in a news release.

Lung cancer is the number one cause of cancer-related death in both men and women. The disease is likely to be diagnosed in some 228,190 people this year, and is predicted to kill about 159,480, the U.S. National Cancer Institute said. EGFR mutations are found in about 10 percent of NSCLC cases.
 
Gilotrif is designed to block proteins that spur development of cancer cells, the FDA said. The drug was approved along with a companion diagnostic called the therascreen EGFR RGQ PCR Kit, which helps doctors determine if a person's lung cancer cells express the EGFR mutations.
 
Gilotrif's safety and effectiveness were evaluated in clinical studies involving 345 people with spreading NSCLC whose tumors had EGFR mutations. The most common side effects were skin breakouts, dry and itchy skin, mouth inflammation, infection near the nails and decreased weight and appetite.
 
Among those who received Gilotrif, progression-free survival was 4.2 months longer than those who received chemotherapy, the FDA said. There was no statistically significant difference in overall survival, the agency added.
 
Gilotrif is produced by Ridgefield, Conn.-based Boehringer Ingelheim Pharmaceuticals. The companion diagnostic is manufactured by the British firm Qiagen Manchester Ltd.

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

New Painkiller Discourages Abuse

Thursday, 24 Jul 2014 16:38 PM

A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the dr . . .

Zydelig Treats Three Types of Blood Cancer

Wednesday, 23 Jul 2014 17:02 PM

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat t . . .

Help for Hereditary Angioedema

Friday, 18 Jul 2014 08:36 AM

Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease th . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved